瑞博西尼 Ribociclib Ribociclib Free Base, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway,
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
帕布昔利布 Palbociclib Palbociclib, also known as PD-0332991, is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
?,斘髂?Abemaciclib Also known as LY2835219, is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antine
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
贊魯替尼 Zanubrutinib Zanubrutinib, aslo known as BGB-3111, is a potent and highly selective small molecule BTK inhibitor for the potential treatment of a variety of lymphomas.
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商
依魯替尼 Ibrutinib Ibrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity
更新時(shí)間:2023-07-12
廠商性質(zhì):代理商